Travere Therapeutics
TVTX
138 hedge funds and large institutions have $1.42B invested in Travere Therapeutics in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 48 increasing their positions, 41 reducing their positions, and 22 closing their positions.
48% more capital invested
Capital invested by funds: $961M → $1.42B (+$462M)
27% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 22
17% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 41
3% more funds holding
Funds holding: 134 → 138 (+4)
0.22% more ownership
Funds ownership: 102.24% → 102.46% (+0.22%)
22% less call options, than puts
Call options by funds: $3.51M | Put options by funds: $4.49M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$30.7M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$23M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$11.1M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$11.1M |
| 5 |
Janus Henderson Group
London,
|
+$9.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$35.5M |
| 2 |
SCM
Scopia Capital Management
New York
|
-$13.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$11.1M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$10.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.82M |
TVTX Hedge Fund Activity: Q4 2020 in Review
138 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q4 2020, worth a combined $1.42B — up 48% from $961M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new TVTX positions and 22 closed out — a net gain of 6 holders — while 48 added to existing stakes and 41 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $30.7M. The largest seller was State Street, exiting entirely with an estimated $35.5M sold.
- 138 institutional investors held Travere Therapeutics (TVTX) as of Q4 2020, up from 134 in Q3 2020.
- Funds reported $1.42B of Travere Therapeutics stock for Q4 2020, up 48% quarter-over-quarter.
- 28 funds opened new Travere Therapeutics positions in Q4 2020 and 22 closed out, a net change of +6 holders.
- The largest Travere Therapeutics buyer in Q4 2020 was Adage Capital Partners, an estimated $30.7M added.
- The largest Travere Therapeutics seller in Q4 2020 was State Street, an estimated $35.5M sold.
Based on aggregated 13F filings for Q4 2020.